[riccd2001]

Here's the related eligible terms to participate in future upcoming clinical trials...

"Ages Eligible for Study:18 Years and older

Genders Eligible for Study:Both

Accepts Healthy Volunteers:no

Criteria: Inclusion Criteria: - Histologic diagnosis of primary or de novo MDS using WHO classification - Non-del(5q) low or Intermediate-1risk MDS - ECOG performance status of 0-1 - Documented significant cytopenia for at least 2 months - Must have discontinued growth factors (EPO, G-CSF, GM-CSF) for at least 21 days prior to study entry - All study participants must be registered into the mandatory RevAssist® program and be willing and able to comply with the requirements of RevAssist® - Females of childbearing potential should have two negative serum pregnancy tests with a sensitivity of at least 50 mIU/mL. The first test should be performed within 10-14 days, and the second test within 24 hours of prescribing lenalidomide (prescriptions must be filled within seven days) Exclusion Criteria: - Known hypersensitivity to Telintra™ (intravenous or oral) - Known prior therapy with or hypersensitivity to thalidomide or lenalidomide - Prior allogenic bone marrow transplant for MDS - History or prior malignancy - Except for treated carcinoma of uterine cervix, basal cell or squamous cell skin cancer, or other cancers (e.g. breast, prostate) for which patient has been disease-free for at least 3 years. - MDS evolving from: - A pre-existing myeloproliferative disorder - An autoimmune disease - Secondary to prior treatment with radiation or chemotherapy - History of MDS IPSS score>1.0 - Pregnant or lactating women - Leptomeningeal or leukemic meningitis - Prior treatment with DNA methyltransferase inhibitors (DMTI) [e.g., azacitadine, decitabine, etc.]"